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Key messages
What is already known about this subject?
 ► With better treatment outcomes, it is nowadays 
common to taper medication in patients with 
rheumatoid arthritis who are in sustained 
remission. The optimal tapering approach still 
has to be unravelled.
What does this study add?
 ► This study compares the effectiveness of 
gradual tapering the conventional synthetic 
disease-modifying antirheumatic drugs 
(csDMARD) or the TNF inhibitor in patients with 
rheumatoid arthritis with controlled disease 
treated with a combination of csDMARDs and a 
TNF inhibitor.
 ► The TApering strategies in Rheumatoid Arthritis 
(TARA) trial is one of the first trials which 
assesses differences in tapering strategies, and 
elaborates on current viewpoints concerning 
tapering treatment, instead of only determining 
if tapering is feasible or not.
How might this impact on clinical practice or 
future developments?
 ► Tapering TNF inhibitors was not superior to 
tapering csDMARDs. We, therefore, advise 
to taper the TNF inhibitor first. This supports 
current EULAR guidelines.
AbsTRACT
Objectives The aim of this study is to evaluate the 
effectiveness of two tapering strategies after achieving 
controlled disease in patients with rheumatoid arthritis 
(Ra), during 1 year of follow-up.
Methods in this multicentre single-blinded (research 
nurses) randomised controlled trial, patients with Ra 
were included who achieved controlled disease, defined 
as a Disease activity score (Das) ≤ 2.4 and a swollen 
Joint Count (sJC) ≤ 1, treated with both a conventional 
synthetic disease-modifying antirheumatic drugs 
(csDMaRD) and a TnF inhibitor. eligible patients were 
randomised into gradual tapering csDMaRDs or TnF 
inhibitors. Medication was tapered if the Ra was still 
under control, by cutting the dosage into half, a quarter 
and thereafter it was stopped. Primary outcome was 
proportion of patients with a disease flare, defined as 
Das > 2.4 and/or sJC > 1. secondary outcomes were 
Das, european Quality of life-5 Dimensions (eQ5D) 
and functional ability (Health assessment Questionnaire 
Disability index [HaQ-Di]) after 1 year and over time.
Results a total of 189 patients were randomly assigned 
to tapering csDMaRDs (n = 94) or tapering anti-TnF (n 
= 95). The cumulative flare rates in the csDMaRD and 
anti-TnF tapering group were, respectively, 33 % (95% 
Ci,24% to 43 %) and 43 % (95% Ci, 33% to 53 % (p 
= 0.17). Mean Das, HaQ-Di and eQ-5D did not differ 
between tapering groups after 1 year and over time.
Conclusion Up to 9 months, flare rates of tapering 
csDMaRDs or TnF inhibitors were similar. after 1 year, a 
non-significant difference was found of 10 % favouring 
csDMaRD tapering. Tapering TnF inhibitors was, 
therefore, not superior to tapering csDMaRDs. From a 
societal perspective, it would be sensible to taper the 
TnF inhibitor first, because of possible cost reductions 
and less long-term side effects.
Trial registration number nTR2754
InTROduCTIOn
Treatment outcomes of rheumatoid arthritis 
(RA) have improved enormously during the past 
decades due to earlier detection of the disease, a 
treat-to-target approach and intensified treat-
ment, especially combination therapy with 
conventional synthetic disease-modifying antirheu-
matic drugs (csDMARDs) and biological DMARDs 
(bDMARDs). As a result, 50%–60% of patients 
with early RA are able to reach low disease activity 
or even sustained remission.1–4 Because of these 
improved outcomes, it is nowadays more common 
to taper medication in patients with RA, who are 
in sustained remission. This is in accordance with 
current treatment guidelines.4 However, an optimal 
tapering approach, including in which order, still 
has to be unravelled.
The benefits of tapering treatment are: (1) a 
decreased risk of long-term adverse events due to 
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immunosuppression, that is, increased infection risk and possi-
bility of malignancy development, (2) a reduction of healthcare 
costs, especially when biologicals are tapered and (3) a possibly 
improved compliance.5 6 On the other hand, tapering treatment 
may lead to more transient or persistent disease flares with 
potential harmful consequences.1 7 8
Previous studies have shown that it is possible to taper 
DMARDs in various ways, which has been extensively reviewed 
by several research groups.7 9–15 bDMARDs are most frequently 
completely withdrawn. However, with this tapering strategy, 
the risk of disease flares in the first year of follow-up is very 
high. Other bDMARD-tapering studies used a dose-reduction 
approach, which resulted in less disease flares. However, to 
our knowledge, no randomised trials have been performed that 
investigate which DMARD should be tapered first.
Therefore, the aim of this study is to compare the effectiveness 
of two tapering strategies, namely gradually tapering csDMARDs 
or tumor necrosis factor (TNF) inhibitors, in patients with RA 




Data were used from a clinical trial (NTR2754)—namely, 
TApering strategies in Rheumatoid Arthritis (TARA). TARA, a 
multicentre, single-blinded (research nurses) randomised trial, 
was carried out in 12 rheumatology centres in the Southwestern 
part of the Netherlands. Inclusion started in September 2011 
and ended July 2016.
Patients
Adult patients with RA with controlled disease, defined as a 
Disease Activity Score (DAS) ≤2.4 and a Swollen Joint Count 
(SJC) ≤1 at two consecutive time points within a 3-month 
interval, with a combination of a csDMARD and TNF inhib-
itor, were included. Exclusion criteria were: (1) not being able to 
understand, speak and write in Dutch; (2) being diagnosed with 
a psychiatric or personality disorder and (3) tapering or stopping 
therapy due to other reasons.
Randomisation and blinding
Patients were randomised using minimisation randomisation 
stratified for centre. Trained research nurses, blinded to the allo-
cated treatment arm throughout the study, examined patients 
and calculated the DAS.
Tapering schedule
Patients were randomised into gradual tapering their csDMARD 
or TNF inhibitor. csDMARD tapering was realised by cutting 
the dosage into half, a quarter and thereafter it was stopped. 
The TNF inhibitor was tapered by doubling the dose interval, 
followed by cutting the dosage into half, and thereafter it was 
stopped. The total tapering schedule took 6 months, with dose 
adjustments every 3 months as long as there was still a controlled 
disease. At the start of the study, patients were asked to refrain 
from glucocorticoids (GCs). There were no restrictions on 
the use of non-steroidal anti-inflammatory drugs (NSAIDs) or 
intra-articular GC injections.
If a disease flare occurred, defined as DAS >2.4 and/or SJC 
>1, tapering was stopped and the last effective treatment, when 
RA was under control, was restarted. In case of a flare, one intra-
muscular GC injection was allowed as bridging therapy. After a 
flare, no further attempts were taken to taper medication during 
the remainder of the first year of follow-up.
Outcomes
The primary outcome was the proportion of patients with a 
disease flare within 1 year. Secondary endpoints were disease 
activity, functional ability, quality of life, medication usage and 
radiographic progression.
Disease activity was measured with the DAS. Functional 
ability was measured with the Health Assessment Questionnaire 
Disability Index (HAQ-DI).16 Higher HAQ-DI scores indicate 
poorer function. Quality of life was measured with the Euro-
pean Quality of Life-5 Dimensions (EQ-5D) and Short Form-36 
(SF-36).17–19 A higher EQ-5D index or SF-36 score indicates a 
better quality of life. Radiographic progression was measured 
with the modified total Sharp score (mTSS).20 Radiographs were 
scored chronologically by two out of three qualified assessors, 
who were blinded for study allocation and the identity of the 
patients.21 Median mTSS are reported.22 The weighted overall 
κ was 0.75 with >99% agreement. The percentage of patients 
with radiographic progression, defined as a change in mTSS 
>0.5 and >0.9 (the smallest detectable change), are given.22
Follow-up and assessments
Treatment strategies were tightly controlled, with patients being 
examined at baseline and every 3 months thereafter. At each 
time point, the DAS, medication usage, development of compli-
cations and self-reported questionnaires were collected, except 
for hand and foot radiographs, which were obtained at baseline 
and after 1 year of follow-up.
safety monitoring
Safety monitoring took place according to Dutch guidelines, and 
included laboratory tests every 3 months.23–25 The medication 
was stopped or the dosage was lowered in case of adverse events 
related to medication use.
statistical analysis
The TARA study was a superiority trial, powered to detect a 20% 
difference in flare rates between both tapering strategies. Based 
on related prospective cohort studies from 2011 and before, 
following assumptions were made: (1) 40% of the patients 
tapering their TNF inhibitors to half will have controlled disease 
after 6 months and (2) 60% of the csDMARD tapering group 
will have controlled disease after 6 months.26–28 Therefore, to 
detect this 20% difference using a significance level of α=0.05 
and a power of 80%, 107 patients were needed in each treat-
ment arm, also taking a 10% drop-out ratio into account.
Outcomes were calculated in an intention-to-treat analysis, 
using all available data. Differences in cumulative flare rates 
between groups were analysed with a logistic regression model. 
To account for stratified randomisation by centre, intercepts for 
each centre were included. Flare-free survival was visualised 
with Kaplan-Meier curves. Descriptive statistics were used to 
assess the proportion of patients with a controlled disease after 
12 months of follow-up. A linear mixed model with maximum 
likelihood optimisation was used to compare DAS, HAQ-DI 
and EQ-5D over time. Random intercepts were included for 
both hospital and individual patients. Residual correlation was 
modelled by inclusion of an autoregressive order correlation 
structure. In the final model, the differences in evolution over 
time for the outcome DAS, HAQ-DI and EQ-5D between the 
two groups were assessed.
 o
n





is: first published as 10.1136/annrheum
dis-2018-214970 on 6 April 2019. Downloaded from
 
748 van Mulligen E, et al. Ann Rheum Dis 2019;78:746–753. doi:10.1136/annrheumdis-2018-214970
Rheumatoid arthritis
Figure 1 Trial profile and patient participation. Results are shown 
as number of patients. csDMARDs, conventional synthetic disease-
modifying antirheumatic drugs; TNF, tumor necrosis factor.
Table 1 Baseline characteristics of the csDMARD tapering group 







  Age (years), mean (95% CI) 55.9 (53.0 to 58.8) 57.2 (55.0 to 
59.4)
  Gender, female, n (%) 67 (71) 58 (61)
disease characteristics
  Symptom duration (years), median 
(IQR)
6.0 (4.1–8.5) 6.4 (4.2–8.9)
  RF positive, n (%) 50 (57) 59 (65)
  ACPA positive, n (%) 62 (71) 67 (75)
disease activity
  DAS44, mean (95% CI) 1.1 (0.9 to 1.2) 1.0 (0.9 to 1.1)
  DAS clinical remission, DAS44 
<1.6, n (%)
76 (81) 87 (88)
  TJC44, median (IQR) 0 (0–2) 0 (0–1)
  SJC44, median (IQR) 0 (0–0) 0 (0–0)
  VAS disease activity (0–100 mm), 
median (IQR)
20 (4–32) 12 (4–23)
  ESR in mm/hour, median (IQR) 8 (3–14) 8 (2–15)
  CRP in mg/L, median (IQR) 2.2 (1–5) 2 (1–6)
use of csdMARds*
  MTX, n (%) 90 (96) 84 (88)
  SASP, n (%) 10 (11) 12 (13)
  HCQ, n (%) 24 (26) 37 (39)
  Leflunomide, n (%) 2 (2) 4 (4)
use of TnF inhibitor
  Etanercept, n (%) 51 (54) 52 (55)
  Adalimumab, n (%) 37 (39) 40 (42)
  Others, n (%)† 6 (6) 3 (3)
Radiographs (hand/foot)
  mTSS (0–488), median (IQR) 2 (0–6.5) 1 (0–3.5)
  Erosion score (0–280), median 
(IQR)
0 (0–2.5) 0 (0–2)
  JSN score (0–168), median (IQR) 0.5 (0–2.5) 0 (0–2.5)
  Erosive disease, n(%)‡ 37 (39) 26 (27)
Patient-reported outcomes
  HAQ-DI, mean (95% CI) 0.52 (0.42 to 0.62) 0.47 (0.35 to 
0.58)
  SF-36, median (IQR)
   PCS 43 (29–48) 47 (39–51)
   MCS 60 (56–63) 57 (51–62)
  EQ-5D index, mean (95% CI) 0.86 (0.83 to 0.88) 0.87 (0.85 to 
0.89)
*Some patients used a combination of csDMARDs.
†Certolizumab or golimumab.
‡Erosive disease is characterised as having >1 erosion in three separate joints.
ACPA, anticitrullinated protein antibody; CRP, C reactive protein;csDMARD, 
conventional synthetic disease-modifying antirheumatic drug; DAS44, Disease 
Activity Score Measured in 44 joints; EQ5D, European Quality of Life-5 Dimensions; 
ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire 
Disability Index; HCQ, hydroxychloroquine; JSN, joint space narrowing; MCS, 
mental component summary; mTSS, modified Sharp/Van der Heijde score. MTX, 
methotrexate; PCS, physical component summary; RF, rheumatoid factor; SASP, 
sulfasalazine; SF-36, Short Form-36; SJC, Swollen Joint Count; TJC, Tender Joint 
Count; VAS, Visual Analogue Scale;
Statistical comparisons of the baseline characteristics and 
outcomes were made by Student’s t-test, χ2 test or Wilcoxon 
rank-sum test, when appropriate.




A total of 330 patients were assessed for eligibility and 189 
of those were randomly assigned to tapering their csDMARD 
(n=94) or tapering their TNF inhibitor (n=95). Most patients 
who were not eligible did not meet the inclusion criteria for 
remission or refused participation (figure 1). During the first 
year of follow-up, 14 patients withdrew from the study, mainly 
because of refraining from further participation (figure 1).
Table 1 shows the baseline characteristics for both tapering 
strategies. Patients had an average symptom duration of 6.8 
years and were predominantly female (66.1%) with an average 
age of 56.6 years. Baseline mean (SD) HAQ-DI was 0.52 (0.47) 
and 0.47 (0.53) and EQ-5D was 0.86 (0.12) and 0.87 (0.11) for, 
respectively, the csDMARD and TNF inhibitor tapering group.
At baseline, 81% of the csDMARD tapering group and 88% of 
the TNF inhibitor tapering group were in remission (DAS <1.6) 
(table 1). The majority of patients in the csDMARD and TNF 
inhibitor tapering group used methotrexate (respectively, 97% 
and 86%) in combination with etanercept (respectively, 54% and 
55%) or adalimumab (respectively, 39% and 42%). Oral GCs 
were taken by 4 (4%) patients in the csDMARD tapering group 
and 2 (2%) patients in the TNF inhibitor tapering group, while 
NSAIDs were taken by 14 (15%) and 20 (21%) patients (table 1).
 o
n





is: first published as 10.1136/annrheum
dis-2018-214970 on 6 April 2019. Downloaded from
 
749van Mulligen E, et al. Ann Rheum Dis 2019;78:746–753. doi:10.1136/annrheumdis-2018-214970
Rheumatoid arthritis
Figure 2 Percentages flares and Kaplan-Meier curves for maintenance 
of controlled disease in the first 12 months. Percentages with flare 
indicates the cumulative number of patients with flares. Error bars 
indicate 95% CIs. Kaplan-Meier curves indicate loss of controlled 
disease (DAS >2.4 and/or SJC >1) over time. Numbers below the 
Kaplan-Meier curve indicate the number of patients at risk per 
time point. csDMARD, conventional synthetic disease-modifying 
antirheumatic drug; DAS, Disease Activity Score Measured; SJC, Swollen 
Joint Count; TNF, tumor necrosis factor.
Table 2 Clinical response after 12 months for both tapering groups, 
according to intention-to-treat







  DAS44, mean (95% CI) 1.31 (1.17 to 1.46) 1.35 (1.19 to 1.51)
  TJC44, median (IQR) 0 (0–2) 0 (0–3)
  SJC44, median (IQR) 0 (0–0) 0 (0–1)
  VAS disease activity (0–100 
mm), median (IQR)
17 (5–36) 19 (6–42)
  ESR in mm/hour, median (IQR) 11 (5–21) 11 (4–19)
  CRP in mg/L, median (IQR) 2.9 (1–6) 4 (1–9)
  DAS clinical remission, DAS44 
<1.6, n (%)
57 (69) 58 (66)
  ΔDAS44 (T12–T0), mean (95% 
CI)
0.28 (0.16 to 0.40) 0.40 (0.22 to 0.57)
Radiographic progression 
(hand/foot)
  mTSS (0–488), median (IQR) 2 (0–6.5) 1 (0–4)
  Erosion score (0–280), median 
(IQR)
0.5 (0–2) 0 (0–2)
  JSN score (0–168), median 
(IQR)
0.5 (0–2.5) 0 (0–2.5)
  ΔmTSS (T12–T0), median (IQR) 0 (0–0) 0 (0–0)
  Patients with progression >0.5, 
n (%)
4 (5) 5 (6)
  Patients with progression >0.9, 
n (%)
4 (5) 5 (6)
  Erosive disease, n(%)* 37 (44) 30 (34)
Patient-reported outcomes
  HAQ-DI, mean (95% CI) 0.59 (0.46 to 0.73) 0.55 (0.43 to 0.66)
  ΔHAQ-DI (T12-T0), mean 
(95% CI)
0.05 (-0.05 to 0.13) 0.07 (-0.01 to 0.16)
  SF-36, median (IQR)
   PCS 43 (32–50) 44 (35–50)
   MCS 58 (53–62) 59 (51–62)
  EQ-5D index, mean (95% CI) 0.80 (0.76 to 0.84) 0.82 (0.79 to 0.85)
  ΔEQ-5D index (T12–T0), mean 
(95% CI)
−0.06 (-0.09 to 0.02) −0.05 (-0.08 to 0.02)
*Erosive disease is characterised as having >1 erosion in three separate joints.
. JSN; Joint space narrowing, CRP, C reactive protein; DAS44, Disease Activity 
Score Measured in 44 joints; EQ-5D, European Quality of Life-5 Dimensions; ESR, 
erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability 
Index;MCS, mental component summary; PCS, physical component summary;SF-36, 
Short Form-36 ; SJC, Swollen Joint Count; TJC, Tender Joint Count;TNF, tumor 
necrosis factor; VAS, Visual Analogue Scale; csDMARD, conventional synthetic 
disease-modifying antirheumatic drug; mTSS, modified Sharp/Van der Heijde score.
At baseline, respectively, 39% and 27% of patients within the 
csDMARD or TNF inhibitor group had erosive disease.
Outcomes
After 1 year of follow-up, the cumulative flare rate was 33% 
(95% CI, 24% to 43%) in the csDMARD and 43% (95% CI, 
33% to 53%) in the TNF inhibitor tapering group (figure 2). 
This means that 63/94 (67%) in the csDMARD tapering group 
and 54/95 (57%) in the TNF inhibitor tapering group still had 
a well-controlled RA (p=0.17). Of the patients who flared and 
restarted the last effective treatment strategy, 46% regained 
a DAS <2.4 within 3 months, which increased to 67% by 6 
months. Two patients (1%) were unable to get back in remission 
within the first year.
No significant differences were seen in DAS (p=0.72), 
HAQ-DI (p=0.63) and EQ-5D (p=0.58) after 1 year between 
both tapering strategies (table 2). Also over time, the DAS 
(p=0.49) and EQ-5D (p=0.35) were not significantly different 
between both tapering strategies (figure 3). Although the TNF 
inhibitor tapering group seems to have lower HAQ-DI scores 
over time, this was not significantly different (p=0.15) (figure 3). 
Over time, the patients with a disease flare increased and thus 
the proportion of patients with a DAS <2.4 decreased in both 
tapering strategies. A similar trend was seen for the HAQ-DI and 
EQ-5D over time (figure 3).
Median mTSS scores were 2 (IQR 0–6.5) in the csDMARD 
and 1 (IQR 0–4) in the TNF inhibitor tapering group after 1 year 
of follow-up (table 2). Radiographic progression was seen in 5% 
of the csDMARD-tapering group and 6% of the TNF inhibitor 
tapering group (p=0.82). Also, the cumulative probability plots 
were overlapping (figure 3B).
Treatment
After 12 months, 58 patients in the csDMARD-tapering group 
and 45 patients in the TNF inhibitor tapering group completely 
tapered their medication (p=0.09). On the other hand, 8 and 16 
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Figure 3 Disease activity, cumulative probability plot for radiological progression, functional ability and quality of life over time per tapering arm. 
(A, C, D) Error bars indicate 95% CIs. (B) Each point represents radiological progression (T12–T0) of an individual patient, measured with the mTSS 
score at 0 and 12 months. csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS: Disease Activity Score; EQ index, European 
Quality Index; HAQ-DI: Health Assessment Questionnaire disability index; mTSS, modified Sharp/Van Der Heijde score; TNF, tumor necrosis factor.
patients were using the same dosage as at start of the trial. The 
remaining patients were able to taper their medication partially 
(figure 4C). The course of the tapering schedule is visualised 
in figure 4A,B. There was an overall significant difference in 
tapering status after 12 months of follow-up between the two 
tapering strategies (p=0.02). During the follow-up period, 
we found no significant differences in GC and NSAID usage 
between both tapering groups (figure 4D).
Adverse events
In the csDMARD-tapering group, 82 adverse events were self-re-
ported versus 98 in the TNF inhibitor tapering group (online 
supplemental table S1). Serious adverse events (SAEs) were seen 
in 10 (12%) patients tapering csDMARDs and 5 (6%) patients 
tapering TNF inhibitors (p=0.3, online supplemental table S1). 
Reported SAEs were hospitalisation, herpes zoster infection, 
basal cell carcinoma, large cell lung carcinoma and a bruised 
rib. None of the SAEs were considered to be related to the trial 
treatment.
dIsCussIOn
Tapering csDMARDs resulted in a 33% (95% CI, 24% to 43%) 
flare rate (DAS44 >2.4 and/or an SJC>1), while tapering TNF 
inhibitors gave a 43% (95% CI, 33% to 53%) flare rate over a 
1-year period in the randomised controlled TARA trial. At 12 
months, 103 (59%) patients were able to stop either their TNF 
inhibitor or csDMARD, while 47 (37%) patients were using a 
lower dosage. Clinical and patient-reported outcomes were 
comparable in both tapering groups over time and after 1 year 
of follow-up. Also, no significant differences in adverse events 
or radiological progression were seen between both tapering 
strategies.
Nowadays, more patients with RA achieve a state of sustained 
remission, which makes them eligible for tapering treatment. 
This is reflected in current European league against rheumatism 
(EULAR) recommendations for the management for RA. The 
advice is to taper DMARD therapy in patients with RA who are in 
sustained remission in the following ordering: GCs, bDMARDS 
and csDMARDs.4 Our results and the fact that TNF-blockers 
are more expensive than csDMARDs support aformentioned 
tapering order.
The majority of previous tapering trials focused on the with-
drawal of TNF inhibitors alone. Flare rates for tapering TNF 
inhibitors varied between 51% and 77%. The Potential Optimal-
isation of Expediency and Effectiveness of TNF-blockers (POET) 
study, for example, reported a 51.2% flare rate (DAS28 >3.2 or 
ΔDAS28 >0.6) after stopping the TNF inhibitor.7 The Spacing of 
TNF-blocker injections in Rheumatoid ArthritiS Study (STRASS) 
showed a 76.6% flare rate (DAS28 >2.6 or ΔDAS28 >0.6) 
when extending the dosage interval of the TNF inhibitor.14 The 
Dose REduction Strategy of Subcutaneous TNF inhibitors study 
(DRESS) reported a 55% flare rate (ΔDAS28-CRP>0.6) after 
a dose reduction of the TNF inbitor.13 Finally, the PRESERVE 
trial (A Randomized, Double-Blind Study Comparing the Safety 
& Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 
mg, & Placebo in Combination With Methotrexate in Subjects 
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Figure 4 Status of tapering in the first year of follow-up. (A, B) Overview of tapering status per time point. Results are shown as percentages of 
patients. According to protocol, the doses were halved every 3 months, starting at T0, and after 6 months, patients could stop their tapered medication 
when they were still in a controlled disease state. Detailed numbers per time point are given in online supplementary table S2. (C) Tapering status 
after 12 months. Columns indicate the percentage of patients that tapered medication until the indicated amount of the original dose. (D) Overview 
of glucocorticoids and NSAID use in the first year of follow-up. csDMARD, conventional synthetic disease-modifying antirheumatic drug; NSAIDs, non-
steroidal anti-inflammatory drugs.
With Active Rheumatoid Arthritis) reported a 57.4% flare rate 
(DAS28 >3.2) when the TNF inhibitor was stopped, and a 
20.9% flare rate (DAS28 >3.2) when the TNF inhibitor dose 
was cut into half.15 Only few randomised controlled trials inves-
tigated tapering of csDMARDs, but the majority looked at the 
combined tapering of csDMARDs and biologicals. Flare rates 
within these studies varied between 35% and 56%.1 6 29–32
Although flare rates of aforementioned studies are similar to or 
higher than our findings, direct comparison is difficult, because 
of the differences in the study design. The most important study 
design differences are: (1) no common definition for relapse or 
flare, (2) no comparison between tapering of csDMARDs and 
TNF inhibitors, and (3) DMARD therapy could only be tapered 
or stopped once during follow-up. If we would use other criteria 
to define a flare in the TARA population, we would observe 
higher hypothetical flare rates. We would have encountered 
a 74.1% flare rate if using DAS28 >3.2 or ΔDAS28 >0.6, an 
80.5% flare rate if using DAS28 >2.6 or ΔDAS28 >0.6, a 52.3% 
flare rate if we use ΔDAS28-CRP>0.6, and a 39.1% flare rate 
if using DAS28 >3.2. Mostly, these flare rates are higher than 
our reported flare rates, but are similar to previous mentioned 
trials. This indicates that our criteria were more strict than other 
studies, but that flare rates are comparible between the tapering 
studies.
Also, the flare duration was longer in the TARA trial 
compared with other trials, which could be due to the 
measurement intervals of 3 months. If patients did not have 
a controlled disease 3 months after flare, we assumed that 
the duration of flare was 6 months. That might be a reason 
that our results seem to have a long flare duration compared 
with the Dose Reduction or Discontinuation of Etanercept 
in Methotrexate-Treated Rheumatoid Arthritis Patients Who 
Have Achieved a Stable Low Disease Activity-State (DOSERA) 
study or DRESS study, in which they knew the exact duration 
of flare in weeks.12 13
In this study, there are several strengths and limitations. 
Strengths of the study are that we performed a randomised 
controlled trial to asess tapering in patients with RA with a 
controlled disease. The TARA trial is one of the first trials which 
assesses the differences in tapering strategies, and elaborates on 
current viewpoints concerning tapering treatment, instead of 
only determining if tapering is feasible or not.
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Some limitations should be noted as well. First of all, inclu-
sion was terminated earlier due to difficulties with recruiting. 
This was due to the initial inclusion criteria being too strict 
(DAS ≤1.6), and the start of another trial (POET study) which 
used the same pool of eligible patients.7 The study sample size 
was based on a 20% difference between both tapering strat-
egies resulting in 96 patients per arm. We found, however, 
a 10% difference with 85 patients in the csDMARD and 89 
patients in the TNF inhibitor arm. This resulted in a power of 
70% instead of 80%. For this reason, we performed a worst-
case scenario analysis to see if our results were valid. We used 
the following assumptions: (1) all extra included patients in 
the csDMARD tapering group had no flares and (2) all extra 
included patients in the TNF inhibitor tapering group flared. 
This analysis showed an 18% difference in flares, which is still 
below the 20% difference on which our power calculation was 
based. Therefore, we think our current results and conclusions 
are valid.
Second, rheumatologist could have only referred patients 
who achieved low disease activity quickly and had less severe 
disease and, therefore, creating selection bias. However, we 
think that our target population is the same as the one we 
would apply our results to, because those are the patients who 
are suitable for tapering and are willing to taper their medi-
cation. Furthermore, only research nurses, who did the DAS 
assessment, were blinded. Rheumatologists, therefore, knew 
the tapering strategy of their patients. This design was chosen 
to mimic daily practise as much as possible. However, it could 
be a possible source of bias, since rheumatologist might prefer 
one of the two tapering strategies and would possibly treat 
patients differently depending on the tapering strategy.
Third, the time frame of follow-up was only 1 year. Although 
the differences in flare rates were not significantly different 
between both tapering strategies, the largest difference was 
seen at 12 months. Data of the second year are needed to 
investigate if this difference will increase.
Last, we encountered 19% protocol violations, which could 
underestimate the effect of one of the two tapering strategies. 
We analysed the type of violations and we can conclude that 
most protocol violations were randomly distributed over the 
two treatment arms and were made due to a treat-to-target 
approach.
To ensure optimal rheumatic care in the future, efficient use 
of biological treatment is needed.33 By tapering medication, 
costs can be reduced, especially when tapering bDMARDs. 
On the other hand, 38% of the patients in the TARA study 
flared within the first year, which may have a direct impact on 
patients’ lives (i.e, worker productivity and unemployment). 
Therefore, it is important to know which tapering strategy is 
most cost-effective, which will be addressed in a follow-up 
analysis.
In conclusion, the TARA study showed that up to 9 months, 
flare rates of tapering csDMARDs or TNF inhibitors were 
similar. After 1 year, a non-significant difference in flare rates 
was found of 10% in favour of csDMARD tapering. Tapering 
TNF inhibitors was, therefore, not superior to tapering 
csDMARDs. From a societal perspective, it would be sensible 
to taper the TNF inhibitor first, because of possible cost reduc-
tions and less long-term side effects.
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